Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Alterações Neuropsicológicas em Pacientes Recebendo Radioterapia para Metástases Cerebrais

10 de novembro de 2026 atualizado por: National Cancer Institute (NCI)

Um estudo piloto para avaliar as medidas de resultados neuropsicológicos e sua relação com o prognóstico em pacientes que recebem radioterapia para metástases cerebrais

Background:

  • There are no standardized sets of tests to measure changes in neuropsychological functioning in patients treated for brain metastasis (cancer that has spread beyond the original site to the brain).
  • Neuropsychological function has an important effect on quality of life and should be included when determining treatment options.

Objectives:

  • To find out if there is a change in patients cognitive (thinking) and daily functioning after standard radiation treatment for brain metastasis that can be measured with tests.
  • To see if any changes on these tests are related to patients response to radiation therapy.

Eligibility:

- Patients 18 years of age or older who have cancer that has spread to the brain.

Design:

  • Patients receive a 2-week course of radiation therapy to the brain, given daily 5 days a week. Some patients may require stereotactic radiosurgery (an additional boost of radiation therapy to specific sites of brain metastasis).
  • Patients have the following evaluations before and after treatment to determine changes in cognition and functioning:
  • Neuropsychological testing to measure cognitive (thinking) abilities like memory, attention, processing speed, and reading, and fine motor skills.
  • Questionnaires to assess quality of life and daily living skills.
  • Patients have MRI scans and blood and urine tests.
  • At the completion of radiation treatment, patients return to the clinic for follow-up visits at 1, 2, 4, 6, 9 and 12 months for blood and urine tests, physical examination, MRI of the brain, neuropsychological testing and assessments of quality of life and daily living skills.

Visão geral do estudo

Status

Concluído

Condições

Descrição detalhada

Background:

  • Metastatic brain tumors occur more frequently than primary brain tumors and occur in approximately 25 percent of patients who die of cancer each year.
  • The Radiation Therapy Oncology Group (RTOG) developed three prognostic classes using a recursive partitioning analysis (RPA) of a large database. These classes are based on Karnofsky Performance Status (KPS), age and disease status.
  • The RTOG RPA classes do not include neuropsychological function as a measure of outcome.
  • There is no consensus of standardization of test selection to measure changes in neuropsychological functioning in this patient population.
  • Neuropsychological function has an important effect on quality of life and should be included when determining prognosis and treatment options for patients.
  • Neuropsychological functioning is important when determining the effects of treatments and for measuring outcomes in clinical trials.

Objectives:

  • To identify the neuropsychological test scores which detect significant change in neuropsychological functioning in patients receiving radiation therapy for brain metastases.
  • To examine the relationship between neuropsychological function and survival in patients receiving radiation therapy for brain metastases.

Eligibility:

  • Patients aged 18 years and older.
  • Pathologically confirmed primary malignancy with at least one intraparenchymal brain metastasis as identified on brain MRI scan with intravenous contrast.
  • The patient must communicate in English in order to complete the neuropsychological evaluations.

Design:

  • This is a longitudinal study that will administer serial neuropsychological assessments to patients with brain metastases who receive radiation therapy.
  • Patients will undergo a battery of neuropsychological tests prior to radiotherapy (WBRT or WBRT followed by SRS), 2 weeks after completion of radiation therapy, then every 3 months for up to 12 months.
  • The test battery will involve approximately 40 minutes of direct cognitive testing and 15 minutes of questionnaires.

There will be three cohorts of 20 patients each for a total of 60 patients. The three cohorts will be made up of differing histologies and will be sorted on the basis of their RTOG RPA Class.

Tipo de estudo

Observacional

Inscrição (Real)

35

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • National Institutes of Health Clinical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Primary clinical

Descrição

-INCLUSION CRITERIA:

  1. Patients must be 18 years of age or older.

  2. Pathologically confirmed primary malignancy with at least one intraparenchymal brain metastasis as identified on brain MRI scan with intravenous contrast.

    • Cohort 1 (N=20): KPS greater than 70; Age less than or equal to 65; controlled primary tumor and no extracranial metastases.
    • Cohort 2 (N=20): KPS greater than 70 and at least one of the following: age greater than 65, uncontrolled or synchronous primary disease, or extracranial metastases
    • Cohort 3 (N=20): KPS less than 70
  3. Patient must have a primary medical or surgical oncologist in the community or at NCI who is willing to collaborate with the ROB staff in the clinical management of the patient.

  4. All patients must sign a document of informed consent indicating their understanding of the investigational nature and the risks of this study BEFORE any of the protocol related studies are preformed (this does not include routine laboratory tests or imaging studies required to establish eligibility).

  5. Subjects of childbearing or child- fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study.

EXCLUSION CRITERIA:

  1. Cognitively impaired patients who cannot give informed consent, including patients assigned a power of attorney for medical decisions.

  2. Inability to communicate in the English language.

  3. Pre- existing or active psychiatric or neurologic impairments, not caused by the brain metastasis, which, in the opinion of the investigators, will interfere with the proper administration or completion of the protocol.

  4. Prior Therapy

    • Patients must not have been treated for a previous brain metastasis.
    • Patients must not have had previous cranial radiation.
    • Patients must not undergo treatment with an investigational drug for the primary disease within 7 days of baseline neuropsychological testing.
    • Patients must not receive systemic therapy within 7 days prior to baseline neuropsychological testing.
    • Patients who have had surgery for their current brain metastasis must wait at least 7 days before baseline neuropsychological testing.
  5. Concurrent Therapy

    • Treatment of primary malignancy with systemic therapy (chemotherapy or biologic agents) cannot be delivered concurrently with the treatment of the intracranial disease. However, treatment of the primary site with local therapy, either surgery or radiotherapy, can be performed concurrently with the treatment of the intracranial disease.
    • Patients receiving glucocorticoids should be tapered to the lowest possible dose, or stopped altogether, by the treating physician. If glucocorticoid dose is adjusted or given for the first time, the patient must remain on stable dose of glucocorticoids for at least 24 hours prior to initial neurocognitive testing, CT and MR imaging.
  6. Patients needing emergent radiation therapy for their brain metastases will be excluded.

  7. Patients must not have evidence of leptomeningeal metastases.

  8. Patients must not be HIV positive.

  9. Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol investigations.

  10. Pregnant or breast-feeding females are excluded because of the potential mutagenic effects on a developing fetus or newborn.

  11. Clinically significant unrelated systemic illness which in the judgment of the Principal or Associate Investigator would compromise the patient s ability to tolerate this therapy or are likely to interfere with the study procedures or results.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
1/Cohort 1

KPS>70; Age =65; controlled primary tumor and no extracranial metastases

2/Cohort 2

KPS>70 and at least one of the following: age >65, uncontrolled or synchronous primary disease, or extracranial metastases

3/Cohort 3

KPS<70

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Neuropsychological function
Prazo: Completion of study

To examine the relationship between neuropsychological function and survival in patients receiving radiation therapy for brain metastases

Completion of study
Test scores for: Hopkins Vrbl Learning Test recall; WAIS-III Digit Span; the WAIS-III Symbol Search; the Ruff 2 & 7 Selective Attn. The Trailmaking Tst Part B speed z-score; and the Grooved Pegboard Test dominant hand z-score
Prazo: Completion of study

To identify the neuropsychological test scores which detect significant change in neuropsychological functioning in patients receiving radiation therapy for brain metastases

Completion of study

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Strengths and weaknesses in neuropsychological functioning
Prazo: completion of study

To examine the strengths and weaknesses in neuropsychological functioning of patients with brain metastases after radiation therapy

completion of study
RTOG RPA classification
Prazo: completion of study

To examine the relationship between the RTOG RPA classification for brain metastasis survival and baseline neuropsychological functioning

completion of study
North American Adult Reading Test-Short Form (NART-35), Hopkins Verbal Learning Test (HVLT), WAIS-III Digit Span subtest, WAIS-III Symbol Search subtest, Ruff 2 and 7 Selective Attention Test
Prazo: completion of study

To further examine whether other measures from the following battery detect significant change in neuropsychological function or predict prognosis in this patient population

completion of study
Neuropsychological functioning, brain lesions (e.g., number and volume), MRI abnormalities, biomarkers, and disease progression or recurrence
Prazo: completion of study

To investigate the relationship between neuropsychological functioning, brain lesions (e.g., number and volume), MRI abnormalities, biomarkers, and disease progression or recurrence

completion of study
Neuropsychological functioning
Prazo: completion of study

To explore the neuropsychological functioning of patients with brain metastases treated with different therapies (e.g. chemotherapy, corticosteroids, complete surgical resection)

completion of study
neuron specific enolase (NSE), S100B, MMPs and VEGF
Prazo: completion of study

To investigate the role of biomarkers, including neuron specific enolase (NSE), S100B, MMPs and VEGF as potential markers of brain injury and disease progression in the serum, plasma and urine of patients with brain metastases

completion of study
Baseline neuropsychological data
Prazo: completion of study

To gather baseline neuropsychological data on patients with brain metastases for use as a reference in the development of new clinical trials involving this patient population in the ROB

completion of study

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: DeeDee K Smart, M.D., National Cancer Institute (NCI)

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de abril de 2009

Datas de inscrição no estudo

Enviado pela primeira vez

30 de setembro de 2011

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de setembro de 2011

Primeira postagem (Estimado)

3 de outubro de 2011

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

14 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 080214
  • 08-C-0214

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All IPD recorded in the medical record will be shared with intramural investigators upon request.

Prazo de Compartilhamento de IPD

Clinical data available during the study and indefinitely.

Critérios de acesso de compartilhamento IPD

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .